Biodistribution, pharmacokinetics and imaging of 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model

Chang, Cheng-Yen; Yu, Chia-Yu; Chang, Ya-Jane; Hsu, Wei-Chuan; Ho, Chung-Li; Yeh, Chung‐Hsin; Luo, Tsai-Yueh; Lee, Te‐Wei; Ting, Gann

doi:10.1016/j.nucmedbio.2007.02.003

Cited by 71 publications

(50 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26,27 Preclinical studies of 188 Re-liposomes have also shown the acute toxicity 28 and potential of this therapy in colon carcinoma. [29][30][31][32] A simple method of encapsulating rhenium radionuclides into liposomes and Doxil using N,N-bis(2-mercaptoethyl)-N¢,N¢-diethylethylenediamine (BMEDA) with high labeling efficiency and good stability has been reported. 33,34 The labeling efficiency, in vitro stability, pharmacokinetics, and biodistribution of 186 Re-Doxil and 186 Re-PEG-liposomes have been previously evaluated.…”

mentioning

confidence: 99%

Chemoradionuclide Therapy with¹⁸⁶Re-Labeled Liposomal Doxorubicin: Toxicity, Dosimetry, and Therapeutic Response

Soundararajan

Bao

Phillips³

et al. 2011

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

This study was performed to determine the maximum tolerated dose (MTD) and therapeutic effects of rhenium-186 ( 186 Re)-labeled liposomal doxorubicin (Doxil), investigate associated toxicities, and calculate radiation absorbed dose in head and neck tumor xenografts and normal organs. Doxil and control polyethylene glycol (PEG)-liposomes were labeled using Re-Doxil has promising potential, because good tumor control was achieved with limited associated toxicity.

show abstract

mentioning

confidence: 99%

Chemoradionuclide Therapy with¹⁸⁶Re-Labeled Liposomal Doxorubicin: Toxicity, Dosimetry, and Therapeutic Response

Soundararajan

Bao

Phillips³

et al. 2011

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

“…These include prostate cancer, colon cancer and breast cancer. Since our previous findings suggest that 188 Re-liposomes is a Table III. promising candidate for cancer therapy, in C26 murine colon carcinoma ascites (17,18), the solid tumor model (19,20) and the human colorectal solid tumor model (21), this study set out to investigate the therapeutic potential of 188 Re-liposomes, in breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…The procedure for micro-SPECT/CT imaging has been previously described (17). The imaging was accomplished using 64 projections, at 60 sec per projection.…”

Section: Methodsmentioning

confidence: 99%

“…Our previous findings suggest that 188 Re-N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-labeled pegylated liposomes ( 188 Re-liposomes) is a promising agent for cancer therapy, in C26 murine colon carcinoma ascites (17,18), the solid tumor model (19,20) and the human colorectal solid tumor model (21). To evaluate the therapeutic potential of 188 Re-liposomes in other tumor types, the poorly immunogenic BALB/c mouse-derived 4T1 mammary carcinoma (22,23), which shares many characteristics with its human counterpart mammary carcinoma, was used to model human breast cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model

Liu

Lee

et al. 2011

Oncol Rep

Self Cite

View full text Add to dashboard Cite

Abstract. Liposomal doxorubicin (Lipo-DOX) has been widely and successfully used in chemotherapy for breast cancer patients. Since our previous studies found that 188 Rhenium ( 188 Re)-N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-labeled pegylated liposomes ( 188 Re-liposomes) have radiotherapeutic potential in a colon cancer model, and little information is available to make a comparison of the therapeutic efficacy of internal radiotherapy and chemotherapy, this study evaluates the therapeutic efficacy of 188 Re-liposomes and Lipo-DOX, in a 4T1 murine orthotopic breast cancer model. MicroSPECT/CT imaging showed that the highest uptake of 188 Re-liposomes was found at 24 h after intravenous administration. The results of a biodistribution assay also demonstrated that the highest uptake of 188 Re-liposomes in a tumor was 3.03 ± 0.29 (%ID/g) at 24 h, and that the highest tumor to muscle ratio was approximately 17 at 48 h. According to measurements of body weight and survival rate, the maximum tolerated doses (MTD) of 188 Re-liposomes and Lipo-DOX were 37 MBq and 25 mg/kg, respectively. In a study of therapeutic efficacy, mice with 4T1 orthotopic breast tumors that were treated with 188 Re-liposomes (4/5 MTD, 29.6 MBq) or Lipo-DOX (4/5 MTD, 20 mg/kg), showed a significant inhibition of tumor growth. In the small tumor model (50 mm 3 ), the lifespan of 4T1 tumor-bearing mice treated with 188 Re-liposomes and Lipo-DOX was increased by 21.7 and 169.6%, respectively, compared to those treated with normal saline. In the large tumor model (300 mm 3 ), the lifespan of the 188 Re-liposomes and the Lipo-DOX treated group was also increased by 35.2 and 141.2%, respectively. In this study, it was found that Lipo-DOX is better than 188 Re-liposomes, for the treatment of 4T1 breast cancer. A further investigation of combined therapy, in a breast cancer model, using 188 Re-liposomes and Lipo-Dox, to determine whether a synergistic effect exists, is ongoing in our laboratory.

show abstract

“…However, LDL particles can not be reconstituted so easily and remote drug/contrast agent loading into native lipoprotein particles is still a tedious approach currently not being standardized. Amphiphilic substances (drugs or marker molecules) or fatty acid modified chelator complexes can be incorporated in the PL monolayer [70,71]. This has successfully been done in numerous biophysical studies and for diagnostic purposes.…”

Section: Ldls Are Flexible Nanotransporters Circulating In Bloodmentioning

confidence: 99%

Lipoprotein Structure and Dynamics: Low Density Lipoprotein Viewed as a Highly Dynamic and Flexible Nanoparticle

Ruth¹,

Laggner²

2012

Lipoproteins - Role in Health and Diseases

View full text Add to dashboard Cite

Biodistribution, pharmacokinetics and imaging of 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model

Cited by 71 publications

References 22 publications

Chemoradionuclide Therapy with¹⁸⁶Re-Labeled Liposomal Doxorubicin: Toxicity, Dosimetry, and Therapeutic Response

Chemoradionuclide Therapy with¹⁸⁶Re-Labeled Liposomal Doxorubicin: Toxicity, Dosimetry, and Therapeutic Response

Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model

Lipoprotein Structure and Dynamics: Low Density Lipoprotein Viewed as a Highly Dynamic and Flexible Nanoparticle

Contact Info

Product

Resources

About

Biodistribution, pharmacokinetics and imaging of 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model

Cited by 71 publications

References 22 publications

Chemoradionuclide Therapy with186Re-Labeled Liposomal Doxorubicin: Toxicity, Dosimetry, and Therapeutic Response

Chemoradionuclide Therapy with186Re-Labeled Liposomal Doxorubicin: Toxicity, Dosimetry, and Therapeutic Response

Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model

Lipoprotein Structure and Dynamics: Low Density Lipoprotein Viewed as a Highly Dynamic and Flexible Nanoparticle

Contact Info

Product

Resources

About

Chemoradionuclide Therapy with¹⁸⁶Re-Labeled Liposomal Doxorubicin: Toxicity, Dosimetry, and Therapeutic Response

Chemoradionuclide Therapy with¹⁸⁶Re-Labeled Liposomal Doxorubicin: Toxicity, Dosimetry, and Therapeutic Response